Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Jounce Therapeutics Rose 39.3% in March

By Maxx Chatsko – Apr 9, 2019 at 6:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma announced full-year 2018 operating results.

What happened

Shares of Jounce Therapeutics (JNCE -5.51%) jumped more than 39% last month, according to data from S&P Global Market Intelligence. The development-stage company reported full-year 2018 operating results that included $65.2 million in collaboration revenue, compared to $71.6 million in the year-ago period. The decline isn't noteworthy for the pre-commercial biopharma. 

In fact, that's an impressive amount of revenue for such an early stage company. It went a long way in allowing the company to report an operating loss of "only" $31 million in 2018, which allowed Jounce Therapeutics to exit the year with $196 million in cash, cash equivalents, and investments. That said, investors need a reason to get excited about the company's immuno-oncology pipeline after a disastrous clinical trial last summer -- and the business is trying to deliver.

A man holding an arrow pointing up.

Image source: Getty Images.

So what

The lead drug candidate, vopratelimab (formerly JTX-2011), is expected to begin two new phase 2 trials as a combination therapy in 2019, which means preliminary data are expected to be available in 2020. The experimental treatment proved almost completely ineffective against a wide range of solid tumors, both as a stand-alone therapy and combination therapy, in its first major clinical trial reported in June 2018. Wall Street doesn't seem too confident in its potential, but Jounce Therapeutics remains committed to its development nonetheless.

Meanwhile, the second most-advanced drug candidate, JTX-4014, will have a recommended dose determined in 2019. That's a relatively boring milestone, but one that's required before a mid-stage trial can be approved by regulators. It could also become more important if vopratelimab stalls again.

Now what

Considering the company is valued at just $210 million, a far cry from its peak valuation of over $900 million in early 2018, Jounce Therapeutics desperately needs a win in the clinic to regain the trust of investors. While it's possible the company can use what it learned from its first failure to develop more effective treatments, most of its pipeline assets are still in preclinical development. That means investors will need to remain patient -- and can expect a fair amount of volatility in the meantime.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Jounce Therapeutics, Inc. Stock Quote
Jounce Therapeutics, Inc.
$0.87 (-5.51%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.